Originally developed for Type 2 diabetes, GLP-1 drugs like Ozempic and Wegovy prolong natural satiety signals, extending the post-meal fullness phase to support appetite control and weight loss
The study was presented at the Society of Interventional Radiology's 2018 Annual Scientific Meeting